Table 2. Neutralization capacity and reactivity pattern of recombinantly expressed human monoclonal antibodies.
50% neutralization activity (µg/ml) a | |||||||
Group and Clone | original IgG isotype | fibroblasts | endoth. cell | epithel. cell | dendritic cell | reactivity with domain I peptideb | reactivity with domain II peptideb |
SM10 | IgG3/κ | 0.1 | 0,35 | 1,0 | n.d. | + | - |
1G2 | IgG3/λ | 0.2 | 0,5 | 1,5 | n.d. | + | - |
SM12 | IgG1/κ | 0.4 | 0,67 | n.d. | n.d. | + | - |
2C2 | IgG1/κ | 0.6 | 1,8 | n.d. | n.d. | + | - |
SM1-6 | IgG1/λ | 1.3 | 1.3 | 0.3 | 1.3 | - | + |
SM3-1 | IgG1/λ | 1.2 | 1.0 | 0.4 | 1.0 | - | + |
SM4-5 | IgG1/λ | 0.6 | 0.8 | 0.9 | 0.4 | - | + |
SM5-1 | IgG1/λ | 0.3 | 0.2 | 0.2 | 0.3 | - | + |
SM6-5 | IgG1/λ | 0.5 | 0.4 | 0.3 | 0.5 | - | + |
SM11-17 | IgG1/λ | 1.0 | 1.0 | 0.3 | 1.3 | - | + |
every antibody was tested at least 3 times with similar results.
tested by immunofluorescence on transiently transfected Cos7 cells.